Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/InstinetMarch 15, 2018 1:45 PM Alexion Pharmaceuticals (ALXN) PT Raised to $160 at BairdMarch 15, 2018 12:14 PM Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond JamesMarch 15, 2018 12:13 PM RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 ResultsMarch 15, 2018 9:41 AM JPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results March 15, 2018 9:06 AM Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMOMarch 15, 2018 8:57 AM Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)March 15, 2018 6:30 AM